Cargando…
Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry
Tyrosine sulfation is a post-translational modification that facilitates protein-protein interaction. Two sulfated tyrosines (Tys173 and Tys177) were recently identified within the second variable (V2) loop of the major HIV-1 envelope glycoprotein, gp120, and shown to contribute to stabilizing the i...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006643/ https://www.ncbi.nlm.nih.gov/pubmed/27389109 http://dx.doi.org/10.1016/j.ebiom.2016.06.037 |
_version_ | 1782451105552138240 |
---|---|
author | Cimbro, Raffaello Peterson, Francis C. Liu, Qingbo Guzzo, Christina Zhang, Peng Miao, Huiyi Van Ryk, Donald Ambroggio, Xavier Hurt, Darrell E. De Gioia, Luca Volkman, Brian F. Dolan, Michael A. Lusso, Paolo |
author_facet | Cimbro, Raffaello Peterson, Francis C. Liu, Qingbo Guzzo, Christina Zhang, Peng Miao, Huiyi Van Ryk, Donald Ambroggio, Xavier Hurt, Darrell E. De Gioia, Luca Volkman, Brian F. Dolan, Michael A. Lusso, Paolo |
author_sort | Cimbro, Raffaello |
collection | PubMed |
description | Tyrosine sulfation is a post-translational modification that facilitates protein-protein interaction. Two sulfated tyrosines (Tys173 and Tys177) were recently identified within the second variable (V2) loop of the major HIV-1 envelope glycoprotein, gp120, and shown to contribute to stabilizing the intramolecular interaction between V2 and the third variable (V3) loop. Here, we report that tyrosine-sulfated peptides derived from V2 act as structural and functional mimics of the CCR5 N-terminus and potently block HIV-1 infection. Nuclear magnetic and surface plasmon resonance analyses indicate that a tyrosine-sulfated V2 peptide (pV2α-Tys) adopts a CCR5-like helical conformation and directly interacts with gp120 in a CD4-dependent fashion, competing with a CCR5 N-terminal peptide. Sulfated V2 mimics, but not their non-sulfated counterparts, inhibit HIV-1 entry and fusion by preventing coreceptor utilization, with the highly conserved C-terminal sulfotyrosine, Tys177, playing a dominant role. Unlike CCR5 N-terminal peptides, V2 mimics inhibit a broad range of HIV-1 strains irrespective of their coreceptor tropism, highlighting the overall structural conservation of the coreceptor-binding site in gp120. These results document the use of receptor mimicry by a retrovirus to occlude a key neutralization target site and provide leads for the design of therapeutic strategies against HIV-1. |
format | Online Article Text |
id | pubmed-5006643 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-50066432016-09-09 Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry Cimbro, Raffaello Peterson, Francis C. Liu, Qingbo Guzzo, Christina Zhang, Peng Miao, Huiyi Van Ryk, Donald Ambroggio, Xavier Hurt, Darrell E. De Gioia, Luca Volkman, Brian F. Dolan, Michael A. Lusso, Paolo EBioMedicine Research Paper Tyrosine sulfation is a post-translational modification that facilitates protein-protein interaction. Two sulfated tyrosines (Tys173 and Tys177) were recently identified within the second variable (V2) loop of the major HIV-1 envelope glycoprotein, gp120, and shown to contribute to stabilizing the intramolecular interaction between V2 and the third variable (V3) loop. Here, we report that tyrosine-sulfated peptides derived from V2 act as structural and functional mimics of the CCR5 N-terminus and potently block HIV-1 infection. Nuclear magnetic and surface plasmon resonance analyses indicate that a tyrosine-sulfated V2 peptide (pV2α-Tys) adopts a CCR5-like helical conformation and directly interacts with gp120 in a CD4-dependent fashion, competing with a CCR5 N-terminal peptide. Sulfated V2 mimics, but not their non-sulfated counterparts, inhibit HIV-1 entry and fusion by preventing coreceptor utilization, with the highly conserved C-terminal sulfotyrosine, Tys177, playing a dominant role. Unlike CCR5 N-terminal peptides, V2 mimics inhibit a broad range of HIV-1 strains irrespective of their coreceptor tropism, highlighting the overall structural conservation of the coreceptor-binding site in gp120. These results document the use of receptor mimicry by a retrovirus to occlude a key neutralization target site and provide leads for the design of therapeutic strategies against HIV-1. Elsevier 2016-06-26 /pmc/articles/PMC5006643/ /pubmed/27389109 http://dx.doi.org/10.1016/j.ebiom.2016.06.037 Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Cimbro, Raffaello Peterson, Francis C. Liu, Qingbo Guzzo, Christina Zhang, Peng Miao, Huiyi Van Ryk, Donald Ambroggio, Xavier Hurt, Darrell E. De Gioia, Luca Volkman, Brian F. Dolan, Michael A. Lusso, Paolo Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry |
title | Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry |
title_full | Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry |
title_fullStr | Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry |
title_full_unstemmed | Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry |
title_short | Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry |
title_sort | tyrosine-sulfated v2 peptides inhibit hiv-1 infection via coreceptor mimicry |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006643/ https://www.ncbi.nlm.nih.gov/pubmed/27389109 http://dx.doi.org/10.1016/j.ebiom.2016.06.037 |
work_keys_str_mv | AT cimbroraffaello tyrosinesulfatedv2peptidesinhibithiv1infectionviacoreceptormimicry AT petersonfrancisc tyrosinesulfatedv2peptidesinhibithiv1infectionviacoreceptormimicry AT liuqingbo tyrosinesulfatedv2peptidesinhibithiv1infectionviacoreceptormimicry AT guzzochristina tyrosinesulfatedv2peptidesinhibithiv1infectionviacoreceptormimicry AT zhangpeng tyrosinesulfatedv2peptidesinhibithiv1infectionviacoreceptormimicry AT miaohuiyi tyrosinesulfatedv2peptidesinhibithiv1infectionviacoreceptormimicry AT vanrykdonald tyrosinesulfatedv2peptidesinhibithiv1infectionviacoreceptormimicry AT ambroggioxavier tyrosinesulfatedv2peptidesinhibithiv1infectionviacoreceptormimicry AT hurtdarrelle tyrosinesulfatedv2peptidesinhibithiv1infectionviacoreceptormimicry AT degioialuca tyrosinesulfatedv2peptidesinhibithiv1infectionviacoreceptormimicry AT volkmanbrianf tyrosinesulfatedv2peptidesinhibithiv1infectionviacoreceptormimicry AT dolanmichaela tyrosinesulfatedv2peptidesinhibithiv1infectionviacoreceptormimicry AT lussopaolo tyrosinesulfatedv2peptidesinhibithiv1infectionviacoreceptormimicry |